ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Belatacept Every Two Month Maintenance Dosing in Kidney Transplantation: A Randomized, Non-Inferiority Trial

I. R. Badell, R. Parsons, S. Mead, S. Thomas, G. Karadkhele, S. Pastan, C. Larsen

Emory University School of Medicine, Atlanta, GA

Meeting: 2020 American Transplant Congress

Abstract number: 332

Keywords: Co-stimulation, Immunosuppression, Kidney transplantation

Session Information

Session Name: Immunosuppressive Drug Minimization

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:15pm-4:27pm

Location: Virtual

*Purpose: Maintenance immunosuppression with belatacept following kidney transplantation results in a reduced risk of patient death and graft loss as compared to calcineurin inhibitors. However, broad application of belatacept has been in part limited by higher early rejection rates, protective immunity concerns, and logistical barriers related to a monthly (q1m) IV infusion requirement. In a phase II clinical study every 2 month (q2m) belatacept was associated with higher acute rejection rates early after transplant but notable stability in renal function over the long-term. Thus q2m dosing of belatacept could reduce access barriers and improve utilization while maintaining renal allograft function.

*Methods: To determine whether q2m dosing of belatacept is noninferior to standard q1m maintenance, we conducted a prospective, single center randomized trial in low immunologic risk, stable renal transplant recipients. First-time recipients on belatacept were randomly assigned to continue on standard maintenance therapy (5 mg/kg) q1m or receive q2m dosing. The primary objective was a noninferiority comparison of renal function at 12 months between the q1m and q2m groups (based on an equivalence margin of 6.0 ml/min/1.73m2).

*Results: Of 176 recipients assessed for eligibility, 166 met inclusion criteria and were randomized to q1m control group (n=82) or q2m study group (n=84). Study status is complete and undergoing formal analysis, with 77 q1m and 78 q2m subjects completing the 12 month study period. Continuous mean eGFR over the study period was similar between groups (Figure 1), with mean eGFR at 12 months of 72.0 [±1.91] and 71 [±1.75] ml/min/1.73m2 in the q1m and q2m groups, respectively. One borderline rejection was observed in the q1m group and 4 ACRs in the q2m group. Importantly, 3 of 4 q2m ACRs were related to documented noncompliance. No subjects developed DSA in the q1m group and 4 in the q2m group, 3 of which occurred in the noncompliant patients with ACR. Two patient deaths and graft losses occurred in the q1m group while none were observed in the q2m group.

*Conclusions: Pending formal statistical analysis, observed mean eGFRs for transplant recipients maintained on q2m belatacept maintenance therapy suggest noninferiority to standard q1m dosing. As such, less frequent q2m belatacept may be a viable and safe maintenance immunosuppressive strategy in compliant kidney transplant recipients. (ClinicalTrials.gov NCT02560558)

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Badell IR, Parsons R, Mead S, Thomas S, Karadkhele G, Pastan S, Larsen C. Belatacept Every Two Month Maintenance Dosing in Kidney Transplantation: A Randomized, Non-Inferiority Trial [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/belatacept-every-two-month-maintenance-dosing-in-kidney-transplantation-a-randomized-non-inferiority-trial/. Accessed June 6, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences